Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1)-based therapy improves glycaemic control through multiple mechanisms, with a low risk of hypoglycaemia and the additional benefit of clinically relevant weight loss. Since Starling and Bayliss first proposed the existence of intestinal secretions that stimulate the pancreas, tremendous progress has been made in the area of incretins. As a number of GLP-1 receptor agonists (GLP-1 RAs) continue to become available, physicians will soon face the challenge of selecting the right option customized to their patient's needs. The following discussion, derived from an extensive literature search using the PubMed database, applying the terms incretin, GLP-1, exenatide, liraglutide, albiglutide, dulaglutide, lixisenatide, semaglutide, and taspoglutide, provides a comprehensive review of existing and upcoming molecules in the GLP-1 RA class in terms of their structure, pharmacological profiles, efficacy, safety, and convenience. Search Methodology: A literature search was conducted using the PubMed database, applying the terms incretin, GLP-1, exenatide, liraglutide, albiglutide, dulaglutide, lixisenatide, semaglutide, and taspoglutide. Relevant articles were those that discussed structural, pharmacokinetic and pharmacodynamic differences, classification, long-acting and short-acting GLP-1 RAs, phase 3 trials, and expert opinions. Additional targeted searches were conducted on diabetes treatment guidelines and reviews on safety, as well as the American Diabetes Association/European Society for Study of Diabetes (ADA/EASD) statement on pancreatic safety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 3×
“[24] Studies comparing long‐ and short‐acting GLP‐1 RAs typically showed superior HbA1c reduction with long‐acting members.[25,26,48,59] In the AWARD‐1 study, both doses of once‐weekly dulaglutide demonstrated superior glycemic control in terms of HbA1c and fasting glucose versus ExBID.”
BackgroundResultBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 8×
“They are also known to potentially enhance β‐cell proliferation and have anti‐apoptotic effects on these cells, inducing insulin biosynthesis.[10,11] The most frequently reported adverse events associated with this class are nausea, vomiting, and diarrhea, the causes of which are thought to be the effects of GLP‐1 RAs…”
BackgroundInfluentialReduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 1×
“reported reduced incretin effects in patients with type 2 diabetes.[5] In 1993, they demonstrated that, in patients with poorly controlled type 2 diabetes, a single exogenous infusion of GLP‐1 increased insulin levels in a glucose‐dependent manner normalizing fasting hyperglycemia.”
BackgroundKendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 1×
“[5] In 1993, they demonstrated that, in patients with poorly controlled type 2 diabetes, a single exogenous infusion of GLP‐1 increased insulin levels in a glucose‐dependent manner normalizing fasting hyperglycemia.[6] It was subsequently recognized that GLP‐1 is degraded by the ubiquitous protease dipeptidyl peptidas…”
BackgroundDrucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 2×
“[20] In other comparator studies, glycosylated Hb A1c (HbA1c) reduction with adjunctive ExBID was generally similar to that of basal insulin,[21] sulfonylureas,[22,23] and lixisenatide;[24] less than that of liraglutide,[25] and EQW.”
Result
Cited by
Capehorn, M. S., Catarig, A.-M., Furberg, J. K., Janez, A., Price, H. C., Tadayon, S., Vergès, B., & Marre, M. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.101117 · Cited by 412
Sposito, A. C., Berwanger, O., de Carvalho, L. S. F., & Saraiva, J. F. K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0800-2 · Cited by 171
Castellana, M., Cignarelli, A., Brescia, F., Laviola, L., & Giorgino, F. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3082 · Cited by 84
Romera, I., Cebrián-Cuenca, A., Álvarez-Guisasola, F., Gomez-Peralta, F., & Reviriego, J. (2019) · Diabetes Therapy · doi:10.1007/s13300-018-0535-9 · Cited by 77
Hossain, M. A., & Pervin, R. (2018) · Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome · doi:10.1016/b978-0-12-812019-4.00034-9 · Cited by 47
Metadata
- Authors
- Adetunji, O., Kalra, S., Baruah, M., Sahay, R., Unnikrishnan, A., & Uppal, S.
- Venue
- Indian Journal of Endocrinology and Metabolism
- Publisher
- Medknow
- Published
- 2016
- Volume
- 20
- Issue
- 2
- Pages
- 254
- ISSN
- 2230-8210 (ISSN-L)
- OpenAlex
- W2277023506
- Cited by
- 71
- References
- 38
- FWCI
- 11.26
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future. https://app.cochat.ai/papers/10.4103/2230-8210.176351
- The paper
- Adetunji, O., Kalra, S., Baruah, M., Sahay, R., Unnikrishnan, A., & Uppal, S. (2016). Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future. Indian Journal of Endocrinology and Metabolism. https://doi.org/10.4103/2230-8210.176351
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.